In atopic dermatitis, the first interleukin-22 inhibitor to reach late clinical trials is showing uncommonly broad suppression of biomarkers associated with disease activity.

Discover why CLLS is a top speculative Buy, with promising CAR-T therapies, strong big pharma partnerships, and attractive ...

A new vaccine targeting triple-negative breast cancer (TNBC) has shown promising results in its first human clinical trial.

Eli Lilly (LLY) stock gains as the company's next-generation weight loss candidate, retatrutide succeeds in a Phase 3 trial.

An experimental vaccine targeting aggressive triple-negative breast cancer (TNBC) has shown encouraging early results in ...

Triple-negative breast cancer (TNBC) is widely regarded as one of the most aggressive and difficult, often deadly, forms of breast cancer. Unlike other subtypes, TNBC lacks oestrogen receptors (ER), ...

Common pre-workout side effects include restlessness, high blood pressure, and tingling skin. High doses of stimulants and amino acids are usually the cause.

Stocks mostly fell Thursday, a day after major indexes neared closing records following the Federal Reserve's decision to cut ...

Vaccine Was Safe and Well Tolerated at the Maximum Tolerated Dose Results Support Advancement of the Program into Phase 2 Development Combination of Keytruda® and the ...

Insilico Medicine has developed a new class of small molecule inhibitors targeting diacylglycerol kinase alpha (DGKα) designed to restore T cell ...

The obesity treatment space has been generating plenty of headlines – and sales – over the past few years. GLP-1 receptor ...

Human intestinal M cells function as dendritic cell-like antigen-presenting cells, displaying constitutive MHC-II activity ...